Li Wenxiao, Zhao Haiyu, Guo Jiayu, Shi Xianbao, Sun Yixin, He Zhonggui, Sun Bingjun
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Department of Pharmacy, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
J Control Release. 2025 Aug 10;384:113894. doi: 10.1016/j.jconrel.2025.113894. Epub 2025 May 26.
The modular engineering of prodrug nanoassemblies-integrating drug modules, response modules, and modification modules-has emerged as a promising platform for cancer nanomedicines. Despite advances, the mechanistic link between modification modules and the in vivo fate of nanoassemblies remains undefined, particularly regarding how intermolecular interaction forces dictate assembly dynamics, drug release, and therapeutic tradeoffs. To address this issue, we constructed two docetaxel-based prodrug nanoassemblies with diverse modification modules: oleic acid (OA, C18:1 fatty acid) and oleyl alcohol (OAL, C18:1 fatty alcohol), respectively. This approach revealed three key structure-performance relationships: (i) modification modules modulate the type and strength of intermolecular forces within prodrug systems; (ii) intermolecular forces regulate the assembly compactness and stability of nanoassemblies; and (iii) the resulting drug release and pharmacokinetic behavior govern the therapeutic efficacy-to-safety equilibrium. The results demonstrated that OA NAs achieved superior drug release and antitumor efficacy yet faced limitations in nanostructural compactness and biosafety. Conversely, OAL NAs, with reduced oxidative sensitivity, offered a more compact nanostructure, prolonged stability, and improved biosafety in vivo. These findings provided essential structure-performance insights to guide the rational design of prodrug nanoassemblies.
前药纳米组装体的模块化工程——整合药物模块、响应模块和修饰模块——已成为癌症纳米药物的一个有前景的平台。尽管取得了进展,但修饰模块与纳米组装体体内命运之间的机制联系仍不明确,特别是关于分子间相互作用力如何决定组装动力学、药物释放和治疗权衡。为了解决这个问题,我们构建了两种基于多西他赛的前药纳米组装体,分别具有不同的修饰模块:油酸(OA,C18:1脂肪酸)和油醇(OAL,C18:1脂肪醇)。这种方法揭示了三个关键的结构-性能关系:(i)修饰模块调节前药系统内分子间力的类型和强度;(ii)分子间力调节纳米组装体的组装紧密性和稳定性;(iii)由此产生的药物释放和药代动力学行为决定治疗效果与安全性的平衡。结果表明,OA纳米组装体实现了卓越的药物释放和抗肿瘤疗效,但在纳米结构紧密性和生物安全性方面存在局限性。相反,OAL纳米组装体具有降低的氧化敏感性,提供了更紧凑的纳米结构、更长的稳定性和体内改善的生物安全性。这些发现为指导前药纳米组装体的合理设计提供了重要的结构-性能见解。